Aclaris' ATI-2138 Shows Strong Efficacy in Atopic Dermatitis Phase 2a Trial
Event summary
- Aclaris presented Phase 2a trial results for ATI-2138 at the 2026 AAD Annual Meeting, showing 77% improvement in EASI score for atopic dermatitis patients.
- Patients experienced 70% improvement in Body Surface Area (BSA) score, 50% improvement in itch intensity (PP-NRS), and 65% improvement in quality of life (DLQI).
- ATI-2138 demonstrated near complete ITK target occupancy at a low dose (10 mg BID), suggesting potential for low drug burden and improved tolerability.
- The trial was an open-label, single-arm study with 12 weeks of treatment, focusing on safety, tolerability, and efficacy measures.
The big picture
Aclaris' positive Phase 2a results for ATI-2138 reinforce the therapeutic potential of ITK inhibition in atopic dermatitis, positioning the company to compete with established JAK inhibitors. The low-dose efficacy and broad mechanistic rationale suggest potential applications across multiple immuno-inflammatory diseases, though the path to commercialization remains uncertain.
What we're watching
- Clinical Progression
- Whether Aclaris can advance ATI-2138 to Phase 3 trials and secure regulatory approval for atopic dermatitis.
- Competitive Positioning
- How ATI-2138's efficacy and tolerability compare to existing JAK inhibitors in the immuno-inflammatory disease space.
- Market Potential
- The pace at which Aclaris can expand ATI-2138's therapeutic potential to other immuno-inflammatory diseases.
Related topics